嗜酸性谱系垂体腺瘤的治疗现状及分子生物学研究进展  

Recent advances in treatment status and molecular biology of eosinophilic pituitary adenomas

作　　者：王玉明 阎晓玲 张学斌 高欣 黄楹 Wang Yuming;Yan Xiaoling;Zhang Xuebin;Gao Xin;Huang Ying(Graduate School of Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Huaiihu Hospital Affiliated to Nankai University,Tianjin 300350,China;Department of Neurosurgery,Hucuihu Hospital Affiliated to Nankai University,Tiaiyin 300350,China)

机构地区：[1]天津医科大学研究生院,天津300070 [2]南开大学附属环湖医院病理科,天津300350 [3]南开大学附属环湖医院神经外科,天津300350

出　　处：《中华神经医学杂志》2020年第3期241-246,共6页Chinese Journal of Neuromedicine

摘　　要：世界卫生组织(WHO)2017版垂体腺瘤分类更加细致地对垂体腺瘤进行了分类。本研究围绕目前新分类中嗜酸性谱系垂体腺瘤,如生长激素细胞腺瘤、泌乳素细胞腺瘤、促甲状腺激素细胞腺瘤的相关治疗方法及其不足之处进行综述。并通过对其基因突变、基因转录改变和表观遗传学的分析及研究,以期从分子生物学角度搜寻潜在的治疗靶点,从而寻找新的治疗方法。After the publication of pituitary adenoma classification(2017)by WHO,a more detailed classification of pituitary adenomas is performed.This review focuses on the related treatment methods and deficiencies of current new classification of eosinophilic lineage pituitary adenomas,such as growth hormone cell adenoma,prolactin cell adenoma,and thyroid stimulating hormone cell adenoma.Through the analysis and research of gene mutations,gene transcriptional changes and epigenetics,we hope to search for potential therapeutic targets from the perspective of molecular biology to find new therapeutic methods.

关 键 词：嗜酸性谱系 垂体腺瘤 分子生物学 治疗 

分 类 号：R73[医药卫生—肿瘤]